- Home
- HSTM vs PRAX Comparison
HSTM vs PRAX Comparison
Compare HSTM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSTM
- PRAX
- Stock Information
- Founded
- HSTM 1990
- PRAX 2015
- Country
- HSTM United States
- PRAX United States
- Employees
- HSTM N/A
- PRAX N/A
- Industry
- HSTM Computer Software: Programming Data Processing
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- HSTM Technology
- PRAX Health Care
- Exchange
- HSTM Nasdaq
- PRAX Nasdaq
- Market Cap
- HSTM 864.6M
- PRAX 952.1M
- IPO Year
- HSTM 2000
- PRAX 2020
- Fundamental
- Price
- HSTM $26.95
- PRAX $52.00
- Analyst Decision
- HSTM Hold
- PRAX Strong Buy
- Analyst Count
- HSTM 2
- PRAX 10
- Target Price
- HSTM $28.00
- PRAX $93.30
- AVG Volume (30 Days)
- HSTM 191.3K
- PRAX 435.3K
- Earning Date
- HSTM 10-20-2025
- PRAX 11-05-2025
- Dividend Yield
- HSTM 0.46%
- PRAX N/A
- EPS Growth
- HSTM 14.03
- PRAX N/A
- EPS
- HSTM 0.67
- PRAX N/A
- Revenue
- HSTM $295,211,000.00
- PRAX $7,765,000.00
- Revenue This Year
- HSTM $4.90
- PRAX N/A
- Revenue Next Year
- HSTM $5.12
- PRAX $20.00
- P/E Ratio
- HSTM $40.24
- PRAX N/A
- Revenue Growth
- HSTM 3.50
- PRAX 338.45
- 52 Week Low
- HSTM $25.36
- PRAX $26.70
- 52 Week High
- HSTM $34.24
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- HSTM 35.07
- PRAX 56.68
- Support Level
- HSTM $27.04
- PRAX $46.99
- Resistance Level
- HSTM $27.94
- PRAX $55.86
- Average True Range (ATR)
- HSTM 0.56
- PRAX 3.62
- MACD
- HSTM -0.29
- PRAX 0.56
- Stochastic Oscillator
- HSTM 1.09
- PRAX 74.41
About HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.